Protilife products will be distributed in the 270 Familiprix drugstores
in Quebec and New Brunswick
MONTREAL, March 1 /CNW Telbec/ - Ranaz Corporation (TSXV: RNZ) ("Ranaz"
or the "Corporation"), a company specializing in the manufacturing and
marketing of protein and dietary supplements for weight loss and obesity
treatment, announced today that it has signed a distribution agreement through
its subsidiary Protilife Distribution Inc. with Familiprix Inc. for its new
product line. Through this agreement, Protilife brand products, intended for
the general public, will be distributed in the 270 Familiprix drugstores
throughout Quebec and New Brunswick.
This new success, on the heels of other distribution agreements signed
recently by Ranaz, strengthens the Canadian market position of the
Corporation's new brand of Protolife weight-loss products, which will be
available in over 2,000 Canadian sales outlets following its impending launch.
"We are pleased that the Familiprix network will enable us to offer our
Protolife products to an even broader public," said Ranaz President and Chief
Executive Officer Jean Bourassa-Marineau. "Our expertise and reputation in the
innovative formulation and development of effective, delicious products are
solidly established. We have been manufacturing a full line of products for
distribution through specialized channels in Canada, Europe and the United
States for the past 17 years."
Protilife Brand Products
The Protilife brand will enable Ranaz to capitalize on its experience in
developing weight-loss and obesity treatment products by introducing a
mass-market product supported by scientific research. The Corporation wishes
to position this brand to eventually establish itself as a world-class leader
in the development and marketing of quality and effective high-protein weight
loss and health supplements and for its consumer market expertise.
Protilife brand products are aimed at producing rapid weight loss while
providing the nutrients needed to maintain muscle mass. Once an individual
attains a target healthy weight, he or she can follow a Protilife weight
maintenance program, a diet based on the four food groups recommended by the
Canada Food Guide that integrates Protilife products to facilitate weight
About Ranaz Corporation
Ranaz is a corporation specializing in manufacturing and marketing
protein and dietary supplements weight loss and obesity treatment. Its mission
is to design, develop and market nutritional, protein and dietary supplements
under private brands, as well as under its own corporate brands, such as
"Protidiet" and "Protilife". Through its subsidiaries, Ranaz produces
high-quality dietary and protein supplements. Ranaz shares have traded under
the symbol RNZ on the TSX Venture Exchange since December 29, 2006.
About the Familiprix Inc.
Familiprix Inc. groups together close to 270 owner/pharmacists of small
(Familiprix succursale santé) or medium-sized (Familiprix) pharmacies. The
Company specializes in the distribution and retailing of pharmaceutical and
Known for its dynamism and high level of professionalism, Familiprix is
currently experiencing a dazzling growth in the pharmaceutical retail sector.
Over this past year the firm has recorded retail sales of 750 million dollars
With nearly 270 pharmacies throughout Quebec and New Brunswick,
Familiprix Inc. has become a dynamic, innovative and high-growth company.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Martin Vidal, Executive Vice President, Ranaz
Corporation, (450) 491-7106, ext. 213, firstname.lastname@example.org; Jean
Walter, Vice President, MaisonBrison, (514) 731-0000, poste 223,